Stay updated with breaking news from Mark Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Miramar Capital LLC grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 2.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,550 shares of the biopharmaceutical company’s stock after acquiring an additional 555 shares during […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Tuesday, Benzinga reports. They currently have a $98.00 price objective on the biopharmaceutical company’s stock. Several other analysts have also commented on the stock. Royal Bank of Canada lifted their price objective on shares of […]
StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. ITCI has been the subject of several other research reports. Royal Bank of Canada increased their price target on Intra-Cellular Therapies from […]
StockNews.com downgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) from a buy rating to a hold rating in a research report sent to investors on Tuesday. A number of other research analysts have also recently weighed in on ITCI. Morgan Stanley reaffirmed an overweight rating and set a $80.00 price target on shares of […]
Pier Capital LLC grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 147,896 shares of the biopharmaceutical company’s stock after purchasing an additional 5,155 shares during the quarter. Intra-Cellular Therapies comprises 1.2% of Pier Capital LLC’s portfolio, making the stock […]